LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Biomarker Outperforms Current Gold Standard to Detect Brain Shunt Infections

By LabMedica International staff writers
Posted on 15 Sep 2016
Print article
Image: The MicroVue complement sC5b-9 Plus enzyme immunoassay kit (Photo courtesy of Quidel Corporation).
Image: The MicroVue complement sC5b-9 Plus enzyme immunoassay kit (Photo courtesy of Quidel Corporation).
Children treated with cerebrospinal fluid (CSF) shunts to manage hydrocephalus frequently develop shunt failure and/or infections, conditions that present with overlapping symptoms.

The potential life-threatening nature of shunt infections requires rapid diagnosis; however, traditional microbiology is time consuming, expensive, and potentially unreliable. A quick and accurate test for bacterial infection in brain shunts or meningitis would improve the quality and efficiency of patient care and patient outcomes. Such a test would also lower health care expenses by avoiding needless hospitalization and treatment.

Scientists at the University of Alabama (Birmingham, AL, USA) prospectively enrolled 198 consecutive undergoing evaluation and treatment for newly diagnosed hydrocephalus, shunt infection, and versus malfunction. Study samples were collected at the same time as routine lab specimens to provide corresponding laboratory results for each specimen (glucose, protein, hematology indices, gram stain, and culture). Samples were labeled and stored at –20 °C and/or –80 °C for a period of one week on average prior to analysis.

Cerebrospinal fluid (CSF) CSF was assayed for the soluble membrane attack complex (sMAC) by enzyme-linked immunosorbent assay (ELISA) in patients with suspected shunt failure or infection. CSF was obtained at the time of initial surgical intervention. Statistical analysis was performed to assess the diagnostic potential of sMAC in pyogenic-infected versus non-infected patients. Soluble MAC was quantitated using the MicroVue complement sC5b-9 Plus enzyme immunoassay (Quidel Corporation, Athens, OH, USA). The lower limit of detection for the assay was 3.7 ng/mL.

The team used appropriately adjusted cutoff values for maximum sensitivity and specificity, and the sMAC was able to detect 14 of 15 infections in the 248 patients, while the current diagnostic gold standard of bacterial culture was less accurate, detecting only 11 of the 15 infections. At the best cutoff value, the test had excellent diagnostic capability with a sensitivity of 93% and a specificity of 86%. Children with pyogenic shunt infection had significantly increased sMAC levels compared with non-infected patients (3,211 ± 1,111 ng/mL versus 26 ± 3.8 ng/mL).

In infected patients undergoing serial CSF draws, sMAC levels were prognostic for both positive and negative clinical outcomes. Children with delayed, broth-only growth of commensal organisms such as Propionibacterium acnes, Staphylococcus epidermidis had the lowest sMAC levels (7.96 ± 1.7 ng/mL), suggesting contamination rather than shunt infection. The study was first published online on July 7, 2016, in the Journal of Clinical Investigation Insight.

Related Links:
University of Alabama
Quidel
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more